Meijer, Annelot J. M., van den Heuvel-Eibrink, Marry M., Brooks, Beth, Zehnhoff-Dinnesen, Antoinette G. am, Knight, Kristin R., Freyer, David R., Chang, Kay W., Hero, Barbara, Papadakis, Vassilios, Frazier, A. Lindsay, Blattmann, Claudia, Windsor, Rachael, Morland, Bruce, Bouffet, Eric, Rutkowski, Stefan, Tytgat, Godelieve A. M., Geller, James, I, Hunter, Lisa L., Sung, Lillian, Calaminus, Gabriele, Carleton, Bruce C., Helleman, Hiske W., Foster, Jennifer H., Kruger, Mariana, Cohn, Richard J., Landier, Wendy, van Grotel, Martine, Brock, Penelope R., Hoetink, Alexander E. and Rajput, Kaukab M. (2021). Recommendations for Age-Appropriate Testing, Timing, and Frequency of Audiologic Monitoring During Childhood Cancer Treatment An International Society of Paediatric Oncology Supportive Care Consensus Report. JAMA Oncol., 7 (10). S. 1550 - 1559. CHICAGO: AMER MEDICAL ASSOC. ISSN 2374-2445

Full text not available from this repository.

Abstract

IMPORTANCE Ototoxicity is an irreversible direct and late effect of certain childhood cancer treatments. Audiologic surveillance during therapy as part of the supportive care pathway enables early detection of hearing loss, decision-making about ongoing cancer treatment, and, when applicable, the timely use of audiologic interventions. Pediatric oncologic clinical practice and treatment trials have tended to be driven by tumor type and tumor-specific working groups. Internationally accepted standardized recommendations for monitoring hearing during treatment have not previously been agreed on. OBJECTIVE To provide standard recommendations on hearing loss monitoring during childhood cancer therapy for clinical practice. METHODS An Ototoxicity Task Force was formed under the umbrella of the International Society of Paediatric Oncology, consisting of international audiologists, otolaryngologists, and leaders in the field of relevant pediatric oncology tumor groups. Consensus meetings conducted by experts were organized, aimed at providing standardized recommendations on age-directed testing, timing, and frequency of monitoring during cancer treatment based on literature and consensus. Consensus statements were prepared by the core group, adapted following several videoconferences, and finally agreed on by the expert panel. FINDINGS The consensus reached was that children who receive ototoxic cancer treatment (platinum agents, cranial irradiation, and/or brain surgery) require a baseline case history, monitoring of their middle ear and inner ear function, and assessment of tinnitus at each audiologic follow-up. As a minimum, age-appropriate testing should be performed before and at the end of treatment. Ideally, audiometry with counseling before each cisplatin cycle should be considered in the context of the individual patient, specific disease, feasibility, and available resources. CONCLUSIONS AND RELEVANCE This is an international multidisciplinary consensus report providing standardized supportive care recommendations on hearing monitoring in children undergoing potentially ototoxic cancer treatment. The recommendations are intended to improve the care of children with cancer and facilitate comparative research on the timing and development of hearing loss caused by different cancer treatment regimens.

Item Type: Journal Article
Creators:
CreatorsEmailORCIDORCID Put Code
Meijer, Annelot J. M.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
van den Heuvel-Eibrink, Marry M.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Brooks, BethUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Zehnhoff-Dinnesen, Antoinette G. amUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Knight, Kristin R.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Freyer, David R.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Chang, Kay W.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Hero, BarbaraUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Papadakis, VassiliosUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Frazier, A. LindsayUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Blattmann, ClaudiaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Windsor, RachaelUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Morland, BruceUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Bouffet, EricUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Rutkowski, StefanUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Tytgat, Godelieve A. M.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Geller, James, IUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Hunter, Lisa L.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Sung, LillianUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Calaminus, GabrieleUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Carleton, Bruce C.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Helleman, Hiske W.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Foster, Jennifer H.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Kruger, MarianaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Cohn, Richard J.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Landier, WendyUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
van Grotel, MartineUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Brock, Penelope R.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Hoetink, Alexander E.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Rajput, Kaukab M.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
URN: urn:nbn:de:hbz:38-607405
DOI: 10.1001/jamaoncol.2021.2697
Journal or Publication Title: JAMA Oncol.
Volume: 7
Number: 10
Page Range: S. 1550 - 1559
Date: 2021
Publisher: AMER MEDICAL ASSOC
Place of Publication: CHICAGO
ISSN: 2374-2445
Language: English
Faculty: Unspecified
Divisions: Unspecified
Subjects: no entry
Uncontrolled Keywords:
KeywordsLanguage
CISPLATIN-INDUCED OTOTOXICITY; STEM-CELL TRANSPLANTATION; INDUCED HEARING-LOSS; QUALITY-OF-LIFE; PLATINUM CHEMOTHERAPY; SODIUM THIOSULFATE; RISK-FACTORS; CHILDREN; MULTICENTER; CARBOPLATINMultiple languages
OncologyMultiple languages
URI: http://kups.ub.uni-koeln.de/id/eprint/60740

Downloads

Downloads per month over past year

Altmetric

Export

Actions (login required)

View Item View Item